source
- Roche’s divarasib shows survival benefit over Amgen and BMS drugs in KRAS G12C lung cancer trialRoche reported that its experimental KRAS G12C inhibitor divarasib extended overall survival and progression‑free survival in a Phase 3 head‑to‑head study against Amgen’s Lumakra and Bristol Myers…
- Vertex's Casgevy gene therapy receives FDA approval for children with sickle cell disease and beta-thalassemiaVertex announced that its gene therapy Casgevy has been granted FDA approval for use in pediatric patients. The decision expands the therapy's reach beyond adult indications. Casgevy is now author…